Can-Fite BioPharma Ltd. (CANF) shares plunged more than 55% in early trade Monday, after the company announced that its Phase II/III psoriasis trial for the company’s drug candidate CF101 did not achieve its primary endpoint. “We are disappointed that our trial did not meet its primary endpoint. Regretfully, in the PASI 75 and PGA we […]
View the full post at: Can-Fite BioPharma (CANF) Stock Plunges 55 percent